Author

Víctor Mayoral-Varo

Camilo José Cela UniversityORCID 0000-0001-6972-2368Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Bibiana I. FerreiraiD· 2 shared Wolfgang LinkiD· 2 shared Alba Orea‐SoufiiD· 1 shared Ana Luísa De Sousa‐CoelhoiD· 1 shared Bruno SantosiD· 1 shared Carla LopesiD· 1 shared Carlos AmenabariD· 1 shared Cristina Garnés-García· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Bibiana I. FerreiraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TRIB2 supports a high glycolytic phenotype in melanoma cells

Víctor Mayoral-Varo, Ana Luísa De Sousa‐Coelho, Carla Lopes, Óscar H. Martínez-Costa, Paulo Jorge Oliveira, Juan J. Aragón, Bibiana I. Ferreira, Wolfgang Link

This study shows TRIB2 promotes glycolysis in melanoma cells, contributing to therapy resistance and suggesting it as a potential therapeutic target.

bioRxiv · Nov 18, 2025 · PreprintCancer Biology

Pharmacological Modulation of TRIB2 Stability in Melanoma Reveals CDK12/13 as Dominant Regulators and Potential Therapeutic Targets

Víctor Mayoral-Varo, Alba Orea‐Soufi, Lucía Jiménez, Bruno Santos, Carlos Amenabar, Panagiota Kyriakou, Gisela Serrão, Miguel Jociles, Sara Obeso, Cristina Garnés-García, Pablo Fernández-Aroca, Ricardo Sánchez‐Prieto, Bibiana I. Ferreira, Wolfgang Link

This study identifies CDK12/13 as key regulators of TRIB2 stability in melanoma and presents three classes of compounds that effectively eliminate TRIB2 with higher potency than afatinib.

bioRxiv · Jul 17, 2024 · PreprintCancer Biology